



Canadian spotlight 23.1: Key additions from the first half of November 2022

In the first half of November, contributing Canadian evidence-synthesis teams have shared with us three newly completed evidence syntheses which are listed in the table below. From the COVID-END inventory, the syntheses provided insight focused on public-health measures (n=3), and clinical management (n=1).

Taxonomy section	Title	Type of product	Date of last search (and publication)	Evidence synthesis team
<ul style="list-style-type: none"> Public-health measures 	What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose?	Update to a living evidence synthesis	2022-11-09 (published 2022-11-09)	The Montreal Behavioural Medicine Centre, Concordia University
<ul style="list-style-type: none"> Public-health measures 	What is the effectiveness of available COVID-19 vaccines for adults, including for variants of concern?	Update to a living evidence synthesis	2022-11-08 (published 2022-11-09)	Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> Public-health measures 	What is the effectiveness of interventions to get school-aged children and youth caught up with routine vaccinations in the context of the COVID-19 pandemic?	Rapid review	2022-08-25 (published 2022-11-09)	National Collaborating Centre for Methods and Tools
<ul style="list-style-type: none"> Clinical Management 	Evidence brief on protective immunity post infection with Omicron (For those interested in accessing the full copy of the rapid review, please contact phac.ocsoevidencebcscdonneesproba ntes.aspc@canada.ca)	Evidence brief	2022-07-26 (published 2022-07-26)	Emerging Science Group, Public Health Agency of Canada (PHAC)